It is certainly possible that this small-molecule loss of cell surface PD-L1 as observed with compound A treatment could result in bonafide in vivo immunomodulatory activity, which we confirmed in a humanized murine model for colon cancer and in virally infected patient samples. Here, CD274 is linked to malignant colon neoplasm.